Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase a-dependent pathway in infarcted hearts

Tsung-Ming Lee, Wei Ting Chen, Nen Chung Chang

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on arrhythmias remains unknown. The aim of this study was to investigate whether sitagliptin attenuates arrhythmias through inhibiting nerve growth factor (NGF) expression, focusing on cyclic adenosine monophosphate (cAMP) downstream signaling such as protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). Methods and Results: Male Wistar rats were randomized to either vehicle or sitagliptin for 4 weeks starting 24 h after ligating the coronary artery. Post-infarction was associated with increased oxidative stress. Measurement of myocardial norepinephrine levels revealed a significant elevation in vehicle-treated rats compared with sham. Compared with the vehicle, infarcted rats treated with sitagliptin had significantly increased cAMP levels, decreased DPP-4 activity, oxidative stress, NGF levels and immunofluorescence-stained sympathetic hyperinnervation. Arrhythmic scores were significantly lower in the sitagliptin-treated infarcted rats than in vehicle. Ex vivo studies showed that sitagliptin increased the phosphorylated cAMP response element-binding protein (CREB), which can be reversed by H-89 (a PKA inhibitor), not brefeldin A (an Epac inhibitor). Heme oxygenase-1 (HO-1) expression was increased by a PKA agonist but not by an Epac agonist. HO-1 expression was attenuated in KG-501 (a CREB inhibitor)-treated infarcted rats in the presence of a PKA agonist. Conclusions: Sitagliptin protects ventricular arrhythmias by attenuating NGF-induced sympathetic innervation via upregulation of HO-1 expression in a cAMP/PKA/CREB-dependent antioxidant pathway in non-diabetic infarcted rats.

Original languageEnglish
Pages (from-to)2461-2470
Number of pages10
JournalCirculation Journal
Volume79
Issue number11
DOIs
Publication statusPublished - Oct 23 2015

Fingerprint

Dipeptidyl Peptidase 4
Protein Kinases
Cardiac Arrhythmias
Cyclic AMP-Dependent Protein Kinases
Cyclic AMP
Heme Oxygenase-1
Nerve Growth Factor
Cyclic AMP Response Element-Binding Protein
Oxidative Stress
Dipeptidyl-Peptidase IV Inhibitors
Brefeldin A
Proteins
Response Elements
Protein Kinase Inhibitors
Infarction
Fluorescent Antibody Technique
Sitagliptin Phosphate
Wistar Rats
Coronary Vessels
Norepinephrine

Keywords

  • Arrhythmia
  • Cyclic adenosine monophosphate (cAMP)
  • Myocardial infarction
  • Nerve growth factor
  • Reactive oxygen species

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase a-dependent pathway in infarcted hearts. / Lee, Tsung-Ming; Chen, Wei Ting; Chang, Nen Chung.

In: Circulation Journal, Vol. 79, No. 11, 23.10.2015, p. 2461-2470.

Research output: Contribution to journalArticle

@article{f395dfd2a35a40e080eb3e735876d47e,
title = "Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase a-dependent pathway in infarcted hearts",
abstract = "Background: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on arrhythmias remains unknown. The aim of this study was to investigate whether sitagliptin attenuates arrhythmias through inhibiting nerve growth factor (NGF) expression, focusing on cyclic adenosine monophosphate (cAMP) downstream signaling such as protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). Methods and Results: Male Wistar rats were randomized to either vehicle or sitagliptin for 4 weeks starting 24 h after ligating the coronary artery. Post-infarction was associated with increased oxidative stress. Measurement of myocardial norepinephrine levels revealed a significant elevation in vehicle-treated rats compared with sham. Compared with the vehicle, infarcted rats treated with sitagliptin had significantly increased cAMP levels, decreased DPP-4 activity, oxidative stress, NGF levels and immunofluorescence-stained sympathetic hyperinnervation. Arrhythmic scores were significantly lower in the sitagliptin-treated infarcted rats than in vehicle. Ex vivo studies showed that sitagliptin increased the phosphorylated cAMP response element-binding protein (CREB), which can be reversed by H-89 (a PKA inhibitor), not brefeldin A (an Epac inhibitor). Heme oxygenase-1 (HO-1) expression was increased by a PKA agonist but not by an Epac agonist. HO-1 expression was attenuated in KG-501 (a CREB inhibitor)-treated infarcted rats in the presence of a PKA agonist. Conclusions: Sitagliptin protects ventricular arrhythmias by attenuating NGF-induced sympathetic innervation via upregulation of HO-1 expression in a cAMP/PKA/CREB-dependent antioxidant pathway in non-diabetic infarcted rats.",
keywords = "Arrhythmia, Cyclic adenosine monophosphate (cAMP), Myocardial infarction, Nerve growth factor, Reactive oxygen species",
author = "Tsung-Ming Lee and Chen, {Wei Ting} and Chang, {Nen Chung}",
year = "2015",
month = "10",
day = "23",
doi = "10.1253/circj.CJ-15-0515",
language = "English",
volume = "79",
pages = "2461--2470",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "11",

}

TY - JOUR

T1 - Dipeptidyl peptidase-4 inhibition attenuates arrhythmias via a protein kinase a-dependent pathway in infarcted hearts

AU - Lee, Tsung-Ming

AU - Chen, Wei Ting

AU - Chang, Nen Chung

PY - 2015/10/23

Y1 - 2015/10/23

N2 - Background: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on arrhythmias remains unknown. The aim of this study was to investigate whether sitagliptin attenuates arrhythmias through inhibiting nerve growth factor (NGF) expression, focusing on cyclic adenosine monophosphate (cAMP) downstream signaling such as protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). Methods and Results: Male Wistar rats were randomized to either vehicle or sitagliptin for 4 weeks starting 24 h after ligating the coronary artery. Post-infarction was associated with increased oxidative stress. Measurement of myocardial norepinephrine levels revealed a significant elevation in vehicle-treated rats compared with sham. Compared with the vehicle, infarcted rats treated with sitagliptin had significantly increased cAMP levels, decreased DPP-4 activity, oxidative stress, NGF levels and immunofluorescence-stained sympathetic hyperinnervation. Arrhythmic scores were significantly lower in the sitagliptin-treated infarcted rats than in vehicle. Ex vivo studies showed that sitagliptin increased the phosphorylated cAMP response element-binding protein (CREB), which can be reversed by H-89 (a PKA inhibitor), not brefeldin A (an Epac inhibitor). Heme oxygenase-1 (HO-1) expression was increased by a PKA agonist but not by an Epac agonist. HO-1 expression was attenuated in KG-501 (a CREB inhibitor)-treated infarcted rats in the presence of a PKA agonist. Conclusions: Sitagliptin protects ventricular arrhythmias by attenuating NGF-induced sympathetic innervation via upregulation of HO-1 expression in a cAMP/PKA/CREB-dependent antioxidant pathway in non-diabetic infarcted rats.

AB - Background: The effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on arrhythmias remains unknown. The aim of this study was to investigate whether sitagliptin attenuates arrhythmias through inhibiting nerve growth factor (NGF) expression, focusing on cyclic adenosine monophosphate (cAMP) downstream signaling such as protein kinase A (PKA) and exchange protein directly activated by cAMP (Epac). Methods and Results: Male Wistar rats were randomized to either vehicle or sitagliptin for 4 weeks starting 24 h after ligating the coronary artery. Post-infarction was associated with increased oxidative stress. Measurement of myocardial norepinephrine levels revealed a significant elevation in vehicle-treated rats compared with sham. Compared with the vehicle, infarcted rats treated with sitagliptin had significantly increased cAMP levels, decreased DPP-4 activity, oxidative stress, NGF levels and immunofluorescence-stained sympathetic hyperinnervation. Arrhythmic scores were significantly lower in the sitagliptin-treated infarcted rats than in vehicle. Ex vivo studies showed that sitagliptin increased the phosphorylated cAMP response element-binding protein (CREB), which can be reversed by H-89 (a PKA inhibitor), not brefeldin A (an Epac inhibitor). Heme oxygenase-1 (HO-1) expression was increased by a PKA agonist but not by an Epac agonist. HO-1 expression was attenuated in KG-501 (a CREB inhibitor)-treated infarcted rats in the presence of a PKA agonist. Conclusions: Sitagliptin protects ventricular arrhythmias by attenuating NGF-induced sympathetic innervation via upregulation of HO-1 expression in a cAMP/PKA/CREB-dependent antioxidant pathway in non-diabetic infarcted rats.

KW - Arrhythmia

KW - Cyclic adenosine monophosphate (cAMP)

KW - Myocardial infarction

KW - Nerve growth factor

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=84944749153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944749153&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-15-0515

DO - 10.1253/circj.CJ-15-0515

M3 - Article

C2 - 26399925

AN - SCOPUS:84944749153

VL - 79

SP - 2461

EP - 2470

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 11

ER -